Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
10/18/2019
Trade Name:
Botox
Generic Name or Proper Name (*):
onabotulinumtoxinA
Indications Studied:
Treatment of lower limb spasticity in pediatric patients 2 to 17 years of age
Label Changes Summary:
*Safety and effectiveness have been established in pediatric patients 2 to 17 years. *Safety and effectiveness of have been established by evidence from adequate and well-controlled studies of Botox in patients 2 to 17 years with lower limb spasticity. However, treatment Botox for this indication is not intended to substitute for usual standard of care rehabilitation regimens. *A pediatric assessment for Botox demonstrated that it is safe and effective in another pediatric population. However, Botox is not approved for such patient population due to marketing exclusivity for another botulinum toxin. *Safety and effectiveness in pediatric patients below the age of 2 years have not been established. *Information on dosing, adverse reactions, and clinical trials. *Postmarketing study.
PREA(P):
P
Sponsor:
Allergan
NNPS:
FALSE
Therapeutic Category:
Neuromuscular blocking agent
-
-